Organisation paid for research Program year 2025 Source: CMS Open Payments

Waldron Medical Research Development

Neither a doctor nor a teaching hospital

Research payments

$28,222

6 payments

Through program year 2025, Waldron Medical Research Development is reported as receiving $28,222 in research payments, across 6 payments.

By program year

4 rows

Year	Kind	Amount	Payments
2025	Research	$7,500	1
2022	Research	$1,600	1
2021	Research	$3,920	2
2020	Research	$15,202	2

Breakdown

Who paid Research payments · program years 2020–2025

Novartis Pharmaceuticals Corporation $20,722 5 payments
Pfizer Inc. $7,500 1 payment

Studies the money was for Research payments · program years 2020–2025

Monaleesa 3 A Randomized Double Blind Placebocontrolled Study of Ribociclib in Combination With Fulvestrant for the Treatment of Postmenopausal Women With Hormone Receptor Positive Her2 Negative Advanced Breast Cancer Who Have Received No Or Only One Line $11,602 1 payment
Encorafenibbinimetinib Master Protocol An Openlabel Continuation Study for Participants Continuing From Encorafenibbinimetinib Clinical Studies $7,500 1 payment
A Randomized Double Blind Placebo Controlled Study of Lee011 in Combination With Letrozole for the Treatment of Postmenopausal Women With Hormone Receptor Positive Her2 Negative Advanced Breast Cancer Who Received No Prior Hormonal Therapy for Advanced Di $5,200 2 payments
Monaleesa 3 A Randomized Double Blind Placebocontrolled Study of Ribociclib in Combination With Fulvestrant for the Treatment of Postmenopausal Women With Hormone Receptor Positive Her2 Negative Advanced Breast Cancer Who Have Received No Or Only One Line of Prior Endocrine Treatment $2,000 1 payment
A Randomized Double Blind Placebo Controlled Study of Lee011 in Combination With Letrozole for the Treatment of Postmenopausal Women With Hormone Receptor Positive Her2 Negative Advanced Breast Cancer Who Received No Prior Hormonal Therapy for Advanced Disease $1,920 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.